GSK press releases
Follow
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Results from the study demonstrate that N6LS effectively maintained undetectable viral load when combined with long-acting cabotegravir.
